<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142910">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885884</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13020507</org_study_id>
    <nct_id>NCT01885884</nct_id>
  </id_info>
  <brief_title>Supportive Care Intervention-Pancreas</brief_title>
  <acronym>SCI-P</acronym>
  <official_title>A Pilot Trial of an Embedded Collaborative Model of Supportive Care for Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, randomized controlled trial of an embedded collaborative model of
      supportive care designed to improve quality of life and decrease use of unwanted healthcare
      services at the end of life for patients with advanced pancreatic cancer. We will enroll 30
      patients who are receiving treatment at the Hillman Cancer Center for recently diagnosed,
      locally advanced or metastatic pancreatic adenocarcinoma, as well as their accompanying
      caregivers and providers. Patients will be randomized to receive either the supportive care
      intervention or usual care. The purpose of this study is to refine an embedded collaborative
      model of supportive care and to develop protocols for recruitment, randomization, and
      longitudinal data collection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>trial feasibility</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess trial feasibility by monitoring number of eligible patients per clinic day, contact rates, interest rates, enrollment rates, randomization rates, intervention visit completion rates, and outcome assessment completion rates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acceptability of intervention participation</measure>
    <time_frame>3 months (+/- 3 weeks) from patient enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will report the percentage of patients and caregivers who found the intervention acceptable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intervention fidelity</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use post-visit checklists to characterize the number and types of recommended topics covered during each supportive care intervention visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>perceived effectiveness</measure>
    <time_frame>3 months (+/- 3 weeks) from patient enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will report the percentage of patients and caregivers who perceived the intervention to be effective for treating symptoms, understanding their illness, coping, and planning for the future.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in patient quality of life</measure>
    <time_frame>baseline (enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of change in patient quality of life from baseline to 3 months using the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep).  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient healthcare utilization</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of the following patient healthcare utilization outcomes: number and types of chemotherapy regimens, frequency and timing of chemotherapy regimens, number and length (days) of hospital admissions, number and length (days) of ICU admissions, number of emergency department visits, frequency and timing (days before death) of hospice use, place of death.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient quality of life</measure>
    <time_frame>3 months (+/- 3 weeks) from patient enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of patient quality of life at 3 months using the FACT-Hep scale.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>patient illness understanding and care preferences</measure>
    <time_frame>3 months (+/- 3 weeks) from patient enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess range and distribution of patient illness understanding using validated questions about patients' perceptions of curability, life expectancy, acknowledgement of whether or not s/he has a terminal illness, and preferences for comfort-oriented vs life-prolonging treatment.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>change in patient anxiety symptoms</measure>
    <time_frame>baseline (enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess change in patient anxiety symptoms with the Hospital Anxiety and Depression Scale (HADS) administered at baseline and 3 months.  HADS scores will be compiled to assess range and distribution.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>change in patient distress</measure>
    <time_frame>baseline (time of enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of change in patient distress responses from baseline to 3 months, collected with the National Comprehensive Cancer Network (NCCN) Distress Thermometer tool, where patients rate their distress on a visual guide from 0, 'no distress' to 10, 'extreme distress.' Scores will be compiled to assess range and distribution at 3-months.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>change in patient depressive symptoms</measure>
    <time_frame>baseline (enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess change in patient depression from baseline to 3 months with the Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of Mental Disorders: Patient Health Questionnaire (PRIME-MD PHQ-9). HADS and PHQ-9 depression scores will be compiled to assess range and distribution at baseline and 3 months.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>change in caregiver distress</measure>
    <time_frame>baseline (enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of change in caregiver distress responses from baseline to 3 months, collected with the National Comprehensive Cancer Network (NCCN) Distress Thermometer tool.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>change in caregiver burden</measure>
    <time_frame>baseline (enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize the range and distribution of the reported change in caregiving burden from baseline to 3 months, collected with the Zarit Burden Interview and Family Member Concerns scale.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver grief</measure>
    <time_frame>1-3 months after death of enrolled patient</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess caregiver grief after the death of their loved one (enrolled patient), if the patient dies during study participation and up to 2-year follow up.  We will use the Inventory of Complicated Grief to assess how much and how often caregivers are affected by the loss of their loved one and summarize the range and distribution of this data.  Because this is a pilot study, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>change in caregiver anxiety symptoms</measure>
    <time_frame>baseline (enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess change in caregiver anxiety symptoms from baseline to 3 months with the Hospital Anxiety and Depression Scale (HADS).  HADS scores will be compiled to assess range and distribution.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>change in caregiver depressive symptoms</measure>
    <time_frame>baseline (enrollment) to 3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess change in caregiver depressive symptoms from baseline to 3 months with the Hospital Anxiety and Depression Scale (HADS).  HADS scores will be compiled to assess range and distribution.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver perceptions of circumstances surrounding death and preparedness for death</measure>
    <time_frame>1-3 months after death of enrolled patient</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess caregiver perceptions of circumstances surrounding death and preparedness for death using four previously validated questions.  We will summarize range and distribution of responses. Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>quality of life of seriously ill patients</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of patient quality of life using the Quality of Life - Seriously Ill Patients (QUAL-E) score.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>patient emotional acceptance of illness</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of patient emotional acceptance of illness using the PEACE Scale.  Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>patient anxiety</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution of patient anxiety using the Hospital Anxiety and Depression Scale (HADS). Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>patient distress</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution in patient distress responses, collected with the National Comprehensive Cancer Network (NCCN) Distress Thermometer tool, where patients rate their distress on a visual guide from 0, 'no distress' to 10, 'extreme distress.' Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>patient depression</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess patient depression from with the Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of Mental Disorders: Patient Health Questionnaire (PRIME-MD PHQ-9). HADS and PHQ-9 depression scores will be compiled to assess range and distribution. Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver distress</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize range and distribution in caregiver distress responses, collected with the National Comprehensive Cancer Network (NCCN) Distress Thermometer tool. Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver burden</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will summarize the range and distribution of the reported caregiving burden, collected with the Zarit Burden Interview and Family Member Concerns scale. Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver anxiety symptoms</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess caregiver anxiety symptoms with the Hospital Anxiety and Depression Scale (HADS). HADS scores will be compiled to assess range and distribution. Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver depressive symptoms</measure>
    <time_frame>3 months (+/- 3 weeks) after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess caregiver depressive symptoms with the Hospital Anxiety and Depression Scale (HADS). HADS scores will be compiled to assess range and distribution. Because this is a pilot trial, we will not conduct formal tests of efficacy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Supportive Care Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly (minimum) patient &amp; caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive standard oncology care from their oncology providers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Embedded Supportive Care</intervention_name>
    <arm_group_label>Supportive Care Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients:

               -  Adults (â‰¥ 18 years old)

               -  Pathologically-confirmed locally advanced or metastatic pancreatic
                  adenocarcinoma diagnosed within the past 8 weeks

               -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0
                  (asymptomatic), 1 (symptomatic but fully ambulatory), or 2 (symptomatic and in
                  bed &lt;50% of the day)

               -  Planning to receive continued care from an oncologist at the Hillman Cancer
                  Center

               -  Accompanied by a caregiver (family member or friend) at the first visit

          -  Caregivers:

               -  Adults (&gt;= 18 years old)

               -  Family member or friend of an eligible patient

        Exclusion Criteria:

          -  Patients:

               -  Unable to read and respond to questions in English

               -  Not planning to receive continued care from an oncologist at the Hillman Cancer
                  Center

               -  Pancreatic neuroendocrine cancer

          -  Caregivers:

               -  Unable to read and respond to questions in English
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael Schenker, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yael Schenker, MD, MAS</last_name>
    <phone>412.864.2375</phone>
    <email>schenkery@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Greer Tiver, MPH</last_name>
    <phone>412.647.0226</phone>
    <email>tiverg@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI), Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yael Schenker, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Arnold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Chu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathan Bahary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barry Lembersky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rene Claxton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda King, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Yael Schenker, MD, MAS</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Supportive Care</keyword>
  <keyword>Palliative Care</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Embedded, coordinated model of supportive care within oncology care</keyword>
  <keyword>Patient and Caregiver support</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
